Post-earnings recap
Reported
Tue, May 6, 2025
EPS actual
$-1.58
EPS est.
$-1.27
EPS surprise
-24.12%
1-day move
-11.86%
Est. EPS
—
Est. Rev
—
Impl. Move
—
This earnings report indicates that CRISPR Therapeutics is facing challenges, particularly reflected in their EPS miss. The stock dropped 11.86% following the announcement, likely due to investor concerns over the company's financial health and lack of revenue information. Without updated guidance, uncertainty remains about the company's future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.58 | N/A | -24.12% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the current market conditions impacting performance. They highlighted a commitment to strategic initiatives despite the setbacks.
Management acknowledged the challenges faced this quarter.
They emphasized ongoing efforts to improve operational efficiency.